Inhibitor Therapeutics (INTI) Income from Continuing Operations (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Income from Continuing Operations came in at 886425.0 in Q1 2026, down 37.89% YoY from 1427202.26 in Q1 2025, and up 32.12% on a QoQ basis from 1305817.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Income from Continuing Operations data on file, last reported at 886425.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 37.89% year-over-year to 886425.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3607472.0 (down 3.06% YoY) and the FY2025 annual result came in at 3329080.0, up 1.28% from the prior year.
- Income from Continuing Operations climbed to 886425.0 in Q1 2026, from 1305817.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 77567.0 in Q2 2022 to a low of 1455007.0 in Q4 2024.
- A 5-year average of 687271.24 and a median of 674760.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 41.62% in 2022, down 1172.28% in 2022.
- Tracing INTI's Income from Continuing Operations over 5 years: stood at 426991.0 in 2022, then tumbled by 195.3% to 1260891.0 in 2023, then dropped by 15.4% to 1455007.0 in 2024, then advanced by 10.25% to 1305817.0 in 2025, then jumped by 32.12% to 886425.0 in 2026.
- The last three Income from Continuing Operations figures came in at 886425.0 (Q1 2026), 1305817.0 (Q4 2025), and 722184.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -613,933.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -886,425.00 |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -722,184.00 |
| Jun 30, 2025 | -693,046.00 |
| Mar 31, 2025 | -642,846.00 |
| Dec 31, 2024 | -1.46 Mn |
| Sep 30, 2024 | -830,957.00 |
| Jun 30, 2024 | -571,690.00 |
| Mar 31, 2024 | -734,711.00 |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -674,760.00 |
| Jun 30, 2023 | -654,521.00 |
| Mar 31, 2023 | -569,596.00 |
| Dec 31, 2022 | -426,991.00 |
| Sep 30, 2022 | -77,692.00 |
| Jun 30, 2022 | -77,567.00 |
| Mar 31, 2022 | -98,910.00 |
| Dec 31, 2021 | -33,561.00 |
| Sep 30, 2021 | -71,051.00 |
| Jun 30, 2021 | -66,182.00 |